Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2

Jeffreys, Laura ORCID: https://orcid.org/0000-0002-0607-6116, Pennington, Shaun ORCID: https://orcid.org/0000-0002-7160-6275, Duggan, Jack, Caygill, Claire, Lopeman, Rose, Breen, Alastair, Jinks, Jessica, Ardrey, Alison, Donnellan, Samantha, Patterson, Ian ORCID: https://orcid.org/0000-0003-3465-0848, Hughes, Grant ORCID: https://orcid.org/0000-0002-7567-7185, Hong, David W, O'Neill, Paul M, Aljayyoussi, Ghaith, Owen, Andrew, Ward, Steve ORCID: https://orcid.org/0000-0003-2331-3192 and Biagini, Giancarlo ORCID: https://orcid.org/0000-0001-6356-6595 (2022) 'Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2'. International Journal of Antimicrobial Agents, Vol 59, Issue 3, e106542.

Preview

Text (Pre-Proof) J_Antim_Agents_inpress_-Jeffreys2022.pdf - Accepted Version Available under License Creative Commons Attribution. Download (874kB) | Preview

Abstract

A key element for the prevention and management of COVID-19 is the development of effective therapeutics. Drug combination strategies of repurposed drugs offer several advantages over monotherapies, including the potential to achieve greater efficacy, the potential to increase the therapeutic index of drugs and the potential to reduce the emergence of drug resistance. Here, we report on the in vitro synergistic interaction between two FDA approved drugs, remdesivir and ivermectin resulting in enhanced antiviral activity against SARS-CoV-2. Whilst the in vitro synergistic activity reported here does not support the clinical application of this combination treatment strategy, due to insufficient exposure of ivermectin in vivo, the data do warrant further investigation. Efforts to define the mechanisms underpinning the observed synergistic action, could lead to the development of novel therapeutic treatment strategies.

Item Type:	Article
Subjects:	QV Pharmacology > Anti-Inflammatory Agents. Anti-Infective Agents. Antineoplastic Agents > QV 268.5 Antiviral agents (General) QV Pharmacology > QV 4 General works WC Communicable Diseases > Virus Diseases > Viral Respiratory Tract Infections. Respirovirus Infections > WC 505 Viral respiratory tract infections WC Communicable Diseases > Virus Diseases > Viral Respiratory Tract Infections. Respirovirus Infections > WC 506 COVID-19
Faculty: Department:	Biological Sciences > Department of Tropical Disease Biology Biological Sciences > Vector Biology Department
Digital Object Identifer (DOI):	https://doi.org/10.1016/j.ijantimicag.2022.106542
Depositing User:	Cathy Waldron
Date Deposited:	03 Feb 2022 12:06
Last Modified:	06 Apr 2022 14:13
URI:	https://archive.lstmed.ac.uk/id/eprint/19902

Statistics

View details

Actions (login required)

Edit Item